Related Experiment Video
Updated: Jul 1, 2026
A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
Published on: November 6, 2020
A synthetic peptide vaccine induces protective immune responses against Candida albicans infection in
Ander Diez1, Ines Arrieta-Aguirre2, Giulia Carrano1
1Department of Immunology, Microbiology and Parasitology, University of the Basque Country UPV/EHU, Leioa, Spain.
Abstract:
Invasive fungal infections, such as those caused by Candida species, predominantly affects hospitalized and immunocompromised patients. Current mortality rates are expected to rise as drug-resistant fungal species increase and the pool of immunocompromised individuals grows. Today, antifungal treatments show limited effectiveness, underscoring the need for new safe and effective antifungal vaccines. This study investigates the efficacy of a protective immunization strategy with DC stimulated by a synthetic peptide, 3P-KLH, containing epitopes from three Candida albicans proteins (Als3, Hwp1 and Met6) against a model of invasive candidiasis raised in immunosuppressed mice. Immunization effectively stimulated both humoral and cellular immune responses, as indicated by high antibody titers to the synthetic fungal peptide, increased cytokine levels, reduced fungal burden in kidneys and improved survival outcomes following infection. Although the variability in fungal burden in the control group limited the statistical significance for fungal clearance data, immunized mice showed a 64-fold lower fungal burden in renal tissues compared to controls. Cytokine analysis revealed elevated levels of IL-2, IL-17, and IFN-γ, suggesting a strong activation of Th1 and Th17 responses, both essential for antifungal immunity. Survival data further supported the protective effect of the immunogenic agent: 62.5 % immunized mice survived the 21-day post-infection period compared to 100 % mortality in controls. The progressively lower fungal burden over time in surviving mice suggests a sustained immune response that continues to suppress fungal replication. These results suggest that the immunization with the synthetic peptide stimulates a strong immune response, involving both antibody production and cell-mediated immunity, making it a promising candidate for therapeutic strategies against invasive candidiasis. Future work should focus on optimizing this immunization approach, assessing long-term immunity, and evaluating its potential in other fungal infection models.
Insights
A novel synthetic peptide vaccine effectively protected immunosuppressed mice against invasive fungal infections caused by Candida species, demonstrating improved survival and reduced fungal burden through robust immune responses.
Area of Science:
- Immunology
- Infectious Diseases
- Vaccine Development
Background:
- Invasive fungal infections, particularly candidiasis, pose a significant threat to hospitalized and immunocompromised individuals.
- Rising drug-resistant fungal strains and an expanding immunocompromised population necessitate novel antifungal therapies.
- Current antifungal treatments exhibit limited efficacy, highlighting the urgent need for effective antifungal vaccines.
Purpose of the Study:
- To evaluate the efficacy of a synthetic peptide (3P-KLH) vaccine in a mouse model of invasive candidiasis.
- To assess the vaccine's ability to induce protective humoral and cellular immune responses against Candida albicans.
Main Methods:
- Mice were immunized with dendritic cells (DCs) stimulated by a synthetic peptide (3P-KLH) containing epitopes from Als3, Hwp1, and Met6 proteins of Candida albicans.
- Immunized and control mice were challenged with invasive candidiasis.
- Humoral (antibody titers) and cellular (cytokine levels) immune responses were measured.
- Fungal burden in kidneys and survival rates were assessed post-infection.
Main Results:
- Immunization with 3P-KLH-stimulated DCs induced significant antibody titers and elevated levels of key cytokines (IL-2, IL-17, IFN-γ), indicating Th1 and Th17 activation.
- Vaccinated mice exhibited a 64-fold reduction in renal fungal burden compared to controls.
- A survival rate of 62.5% was observed in the immunized group over 21 days, versus 0% in the control group.
Conclusions:
- The synthetic peptide immunization strategy effectively elicits both humoral and cell-mediated immunity against invasive candidiasis.
- This vaccine approach shows promise as a potential therapeutic strategy for combating invasive fungal infections.
- Further research is warranted to optimize the vaccine, assess long-term immunity, and explore its efficacy in other fungal infection models.
Related Concept Videos
01:27Cryptococcal Meningitis
01:20Candidiasis